Where is VeloxDX located?

VeloxDX is headquartered in Calgary, Canada.

Is VeloxDX a funded company?

VeloxDX is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does VeloxDX rank among its competitors?

VeloxDX ranks 123rd amongst 96 active competitors, of which 30 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was NOWDiagnostics, which secured $242K in Sep, 2025.

Who are the top competitors of VeloxDX?

VeloxDX's top competitors include OpGen, DNA Electronics and Earth Science tech. Among them, NOWDiagnostics secured the most recent funding round in September, 2025.

VeloxDX - 2026 Company Profile & Competitors

Company Details

Developer of rapid diagnostic tests for detecting urinary tract infections. This technology utilizes electrochemical sensing to identify specific urinary biomarkers associated with bacterial pathogens. The diagnostic platform provides results at the point of care to assist with clinical decision-making. By detecting pathogen-associated chemistry directly in urine samples, the system aims to support targeted treatment choices and reduce reliance on traditional laboratory culture methods. The hardware is designed for integration into clinical workflows to facilitate immediate diagnostic information during patient visits.

Key Metrics

Location

Calgary, Canada

Stage

Unfunded

Ranked

123^rd among 123 competitors

Similar Companies

OpGen & 121 more

View VeloxDX's full profile

VeloxDX has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of VeloxDX include OpGen, DNA Electronics and Earth Science tech. Here is the list of Top 10 competitors of VeloxDX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	OpGen 2002, Rockville (United States), Public	Developer of diagnostics and bioinformatics platforms for providers	$77.5M	Cross Creek, 180 Degree Capital & 12 others	67/100
2nd	DNA Electronics 2003, London (United Kingdom), Series C	Developer of semiconductor‑based DNA‑sequencing systems for use in healthcare	-	Citi, Imperial Innovations & 1 others	54/100
3rd	Earth Science tech 2014, Doral (United States), Public	Developer of a medical device for detection of chlamydia	-	-	52/100
4th	Avails Medical 2013, Menlo Park (United States), Series A	Rapid AST technology for faster, actionable results in bloodstream infections	$8.66M	CARB-X, Linden3 Ventures & 4 others	49/100
5th	HandyLab 1999, Ann Arbor (United States), Acquired	Developer of molecular diagnostic assays and automation platforms	$44M	Dow Chemical Company, Ann Lurie & 7 others	48/100
6th	NOWDiagnostics 2013, Bentonville (United States), Series B	Innovative OTC and point-of-care diagnostic tests providing rapid results	$65.7M	LabCorp, DigitalDx Ventures & 5 others	45/100
7th	Verax Biomedical 1999, Marlborough (United States), Series D	Rapid bacterial detection tests for safer platelet transfusions and cell therapies	$72.3M	KB Partners, Clark Enterprises & 5 others	44/100
8th	Resistell 2017, Basel (Switzerland), Series B	Provider of antibiotic susceptibility testing	$13.4M	OCCIDENT, Hemex & 11 others	42/100
9th	GNA Biosolutions 2010, Planegg (Germany), Series C	Develops instruments, OEM modules and assays for molecular pathogen detection	$20.2M	Bayern Kapital, OCCIDENT & 11 others	41/100
10th	Nanosynex 2017, Tel Aviv (Israel), Acquired	Developer of a rapid diagnostic test for bacterial infections	-	MassChallenge, Technion DRIVE Accelerator ... & 1 others	41/100
123rd	VeloxDX Calgary (Canada), Unfunded	Developer of rapid diagnostic tests for detecting urinary tract infections	-	-	-